As part of Goodwin’s exclusive programming during the BIO International Convention in Boston, we invite you to join us for a session spotlighting the evolving world of M&A and strategic partnerships in a rapidly shifting biotech landscape.

Through a dynamic fireside chat and expert panel discussions, we’ll uncover innovative deal-making strategies, explore how biopharma companies are forging smart alliances, and reveal the pivotal decisions driving growth in unpredictable times.

Don’t miss this opportunity to gain actionable insights, hear from industry insiders, and connect with the leaders shaping the future of biotech. This event is in partnership with PJT Partners.

Please RSVP here and see below for more details!

Date & Time: Wednesday, June 18 from 12:00 PM – 2:30 PM ET

Location: Goodwin’s Boston Office, 100 Northern Avenue, Boston, MA 02210

12:00 – 12:30 PM | Registration and Lunch
12:30 PM – 12:40 PM | Opening Remarks
12:40 PM – 1:15 PM | Fireside Chat: Biopharma Strategy in Volatile Times

• Rob Masella, Partner, Goodwin
• Daniel Lee, Partner, Healthcare Group, PJT Partners

1:15 PM – 2:00 PM | Panel Discussion: Current Perspectives on M&A and Partnering: Finding Strategic Alignment

• Erini Svokos, Partner, Goodwin (Moderator)
• Rajeev Dadoo, PhD, COO & Managing Partner, SR One
• Daniel Rosan, Chief Financial and Business Officer, Ascidian Therapeutics
  2:00 PM – 2:10 PM | Audience Q&A & Closing Remarks

As part of Goodwin’s exclusive programming during the BIO International Convention in Boston, we invite you to join us for a focused discussion on how biotech and pharma companies can protect and maximize the value of their intellectual property. In a time when innovation is critical and IP disputes are on the rise, getting ahead of IP strategy is more important than ever.

Through a candid conversation with leading litigators and experts, we’ll examine real-world disputes, lessons learned, and practical strategies to preserve competitive edge and prepare for what’s ahead.

Please RSVP here and see below for more details!

Date & Time: Wednesday, June 18 from 10:00 AM – 11:30 AM ET

Location: Goodwin’s Boston Office, 100 Northern Avenue, Boston, MA 02210

10:00 – 10:30 PM | Registration
10:30 PM – 11:30 PM | Unlocking the Long-Term Value of Your IP – Lessons from the Trenches

• • Elaine Blais, Partner, Goodwin
  • Robert Frederickson, Partner, Goodwin
  • Emily Rapalino, Partner, Goodwin
  • Daryl Wiesen, Partner, Goodwin
  • Leda Trivinos, Senior Partner, Intellectual Property, Flagship Pioneering

As part of our week of premier programming during the BIO International Convention in Boston, we’re bringing together industry leaders, investors, and strategic advisors for an engaging session on how European biotechs can successfully expand into the US market.

This dynamic lunchtime event will dive into unlocking US capital, driving strategic growth, and navigating the critical legal, business, and partnering pathways that fuel transatlantic success. Hear firsthand lessons from seasoned dealmakers and biotech executives in our expert panels and fireside chat and seize the opportunity to connect with key players shaping the future of global life sciences. This event is in partnership with Danforth Advisors.

Please RSVP here and see below for more details!

Date & Time: Tuesday, June 17 from 11:30 AM – 1:30 PM ET

Location: Goodwin’s Boston Office, 100 Northern Avenue, Boston, MA 02210

11:30 AM – 12:00 PM | Registration and Lunch

12:00 PM – 12:45 PM | Panel: Unlocking US Capital: Legal and Business Pathways – The Mindset for European Biotechs

• Gregg Beloff, Co-Founder and Managing Director, Danforth Advisors
• Robert Puopolo, Partner, Goodwin
• Henry Capper, Managing Director, Head of EMEA BioPharma, J.P. Morgan

12:50 PM – 1:30 PM | Fireside Chat: Partnering and M&A for European Biotechs: Lessons from the Zealand/Roche Experience

• Tim Worden, Partner, Goodwin
• Eric Cox, Chief Commercial Officer, Zealand Pharma

As part of Goodwin’s week of exclusive programming during the BIO International Convention in Boston, we’re excited to invite you to a session focused on China-based NewCos and the dynamics of cross-border dealmaking. China continues to be a dynamic hub for biotech innovation, and companies operating in this space are navigating new opportunities and evolving challenges.

Join us for a morning of insightful conversations exploring what it takes to launch, grow, and expand China-based NewCos—and how to successfully pursue international transactions in a rapidly changing environment. From legal and regulatory foundations to cross-border growth strategies, our expert panels will share practical perspectives and real-world experience to help guide your next move.

Please RSVP here and see below for more details!

Date & Time: Tuesday, June 17 from 8:30 AM – 10:30 AM ET

Location: Goodwin’s Boston Office, 100 Northern Avenue. Boston, MA 02210

8:30 AM – 9:00 AM | Registration and Breakfast

9:00 AM – 9:05 AM | Welcome Remarks

9:05 AM – 9:45 AM | Panel: China NewCos – Strategic and Legal Insights

• Josha Berlin, Head of Corporate Alliances & Business Development, BioCentury Inc. (Moderator)
• David Chen, Partner, Goodwin
• Sue Yao, Executive Director of Licensing and Business Development, Kelun Biotech and Klus Pharma
• Regina Salvat, PhD, Principal, Forbion

9:50 AM – 10:30 AM | Panel: New Challenges and Opportunities in Cross-Border Transactions

• Wendy Pan, Partner, Goodwin (Moderator)
• Alan Wang, Partner, Goodwin
• Jimmy Zhuang, Assistant General Counsel – Business Development, Novo Nordisk
• Tim Opler, Managing Director, Healthcare, Stifel Institutional
• Jon Kiburz, VP Transactions, R&D Business Development, GSK
• Jesús Baena, Director BD&L Oncology, Novartis

Jumpstart your week with a deep dive into the future of medicine as part of Goodwin’s exclusive programming during the BIO International Convention in Boston. Join us for a dynamic symposium where industry leaders and AI pioneers come together to unveil how artificial intelligence is revolutionizing drug discovery. Don’t miss this chance to explore groundbreaking technologies and connect with the minds shaping tomorrow’s healthcare.

RSVP here to attend and see below for more details!

Date & Time: Monday June 16 from 1:00 PM – 4:30 PM ET

Location: Goodwin’s Boston Office, 100 Northern Avenue. Boston, MA 02210

1:00 – 1:30 PM | Registration & Lunch

1:30 – 2:00 PM | Panel: AI Governance and AI Security

• Kaitlin Betancourt, Partner, Goodwin
• Jud Welle, Partner, Goodwin
• Tom Doughty, Chief Information Security Officer, Generate:Biomedicines

2:05 – 2:40 PM | Panel: Diligence Considerations with Tech Acquirers and IP Risks from AI in Drug Discovery and Development

• Marty Gomez, Partner, Goodwin
• Sarah Solomon, Partner, Goodwin
• Robert Carroll, Partner, Goodwin
• Hilary Eaton, CBO, Profluent
• Jen Asher, PhD, Founder and CEO, 1910 Genetics

2:40 – 3:00 PM | Networking/Coffee Break

3:00 – 3:30 PM | Fireside Chat: Advancing a New Era of Programmable Biology Through AI

• Joe Theis, Partner, Goodwin
• Mike Nally, CEO, Generate:Biomedicines

3:35 – 3:45 PM | FDA Insights on AI in Drug Development

• Qi Liu, Co-Chair of CDER AI Council; Lead of CDER AI Review Rapid Response Team, U.S. Food and Drug Administration (virtual)

3:50 – 4:30 PM | Panel: Smarter Drug Development – The Role of AI in Regulatory Strategy

• Julie Tibbets, Partner, Goodwin
• Alexander Morgan, MD, PhD, Partner, Khosla Ventures
• Tracey Sikora, Vice President of Research & Clinical Programs of the National Organization for Rare Disorders (NORD); Co-Founder of Every Cure

Michael Siekman, Huiya Wu, Allegra Padula, and Riley Wyberg will present their data-driven analyses of trends in BPCIA litigation and relevant takeaways.

With 10 years of litigation since the first BPCIA complaint on NEUPOGEN (filgrastim) was filed in 2014, trends are becoming apparent that should cause all biopharma companies to reassess how they protect biologics and plan for biosimilar launch.

Webinar Highlights:

• • Patents Being Asserted: Learn which types of patents are being asserted to block biosimilar competition, how that has changed over time, differences for protein and antibody products, when those patents are being filed during drug development, and differences among Reference Product Sponsors.
  • Trends in BPCIA Litigation: Learn how often and how much of aBLAs are being produced during the Patent Dance, which Biosimilar Manufacturers are producing them, how much the parties dance and who is engaging in the Patent Dance, when cases are settling, and how many asserted patents are carrying through to a final judgment.
  • Real-World Insights: We will share practical recommendations for biologics and biosimilars companies based upon on our analysis and our experience with the BPCIA.

Please RSVP to confirm your attendance.

Attendees at this year’s symposium were optimistic about the potential for progress, citing momentum from new FDA initiatives, growing legislative support, and increased global innovation in research and development. These efforts, alongside increased patient advocacy and a presidential administration focused on speeding patient access, could lead to significant advances in rare disease treatments and cures in 2025.

Read the full insight here.

Goodwin’s Life Sciences team is excited to host its Annual Rare Disease Symposium in Boston on February 5, 2025. Participants are invited to join for an afternoon of engaging fireside chats, inspirational presentations, and networking with peers in the rare disease community.

Please see the agenda below and register to attend in-person or via our virtual webinar to join us.

Agenda

12:00 PM – 1:00 PM EDT | Welcome & Networking Lunch

1:00 PM – 4:30 PM EDT | Rare Disease Symposium Program

• The Patient View
  • David Downing, GRIN1 Dad
  • Jaime McHugh, Rare Disease Mom and NORD Running for Rare Champion
• The Research View
  • Dr. Shira Rockowitz, PhD, Data Science Director, Boston Children’s Hospital, Children’s Rare Disease Collaborative Co-Leader
  • Dr. Piotr Sliz, PhD, Vice President, Chief Research Information Officer & Associate Professor, Boston Children’s Hospital, Children’s Rare Disease Collaborative Co-Leader
• The FDA View
  • Amy Rick, Director of Strategic Coalitions for FDA’s Rare Disease Innovation Hub
• The Policy View
  • Karin Hoelzer, Senior Director, Patient Advocacy, BIO
  • Jack Kalavritinos, Founder, JK Strategies and the Washington Health Innovation Council, and Former Director, HHS Office of Intergovernmental & External Affairs
  • Judy Stecker, SVP, Burson, and Former HHS Deputy Chief of Staff for Strategy & Operations – Rare Disease Parent & Founder, Wheeler’s Warriors
• The View from the National Organization for Rare Disorders
  • Pamela Gavin, Chief Executive Officer, NORD
• The View from the Rare As One Network
  • Heidi Bjornson-Pennell, Senior Program Manager, Science in Society, and Lead, Rare As One Network
• The Biotech CEO View
  • Paula Ragan, PhD, CEO, X4 Pharmaceuticals

4:30 PM – 5:30 PM EDT | Networking Reception

We look forward to kicking off Rare Disease Month with you!

Support Goodwin’s DC Life Sciences Team as they raise money for the National Organization for Rare Disorders (NORD) as part of its “Running for Rare” team at the annual 10K race held during the upcoming DC Marine Corps Marathon on October 27th.

Assist NORD’s mission to drive public policy, accelerate research and improve care for people living with rare diseases by donating here.

Learn more about Goodwin’s Rare Disease Initiative here.

In October, NORD will also hold its annual Breakthrough Summit in Washington, DC on October 20-22, 2024.  This event draws over 1,000 attendees including patients/caregivers, patient advocacy organizations, and healthcare, biotech, and medical technology companies.  Registration is available here. This year, Matt Wetzel will take part in a panel discussion on the growing role of medical devices in the rare disease community.